April 23, 2025

 Vivos Inc. (OTCQB: RDGL), a leader in innovative cancer therapies, announced today a record-breaking first quarter for its IsoPet® Animal Cancer Division. The company’s patented Precision Radionuclide Therapy™ (PRnT™) treated an unprecedented number of pets in Q1 2025, marking a 150% year-over-year increase in treatment volume. This milestone underscores IsoPet®’s growing role as a transformative, non-invasive solution for veterinary oncology.